AviadoBio和Astellas商定一项21.8亿美元的协议,以发展前时性痴呆症基因疗法。 AviadoBio and Astellas agree on a $2.18 billion deal to develop a gene therapy for frontotemporal dementia.

AviadoBio是一家新西兰基因治疗公司,它与日本Astellas公司达成了21.8亿美元的潜在交易,以开发一种前沿时痴呆症治疗办法。 AviadoBio, a New Zealand gene therapy company, has reached a potential $2.18 billion deal with Japanese firm Astellas to develop a treatment for frontotemporal dementia (FTD). 治疗AVB-101旨在阻止FTD的发展,这往往导致在诊断后三至13年内死亡。 The therapy, AVB-101, aims to halt the progression of FTD, which often leads to death within three to 13 years of diagnosis. AviadoBio将提前收到3 000万美元,用于继续人类临床试验,在以前的研究中已经看到了有希望的成果。 AviadoBio will receive $30 million upfront to continue human clinical trials, with promising results already seen in earlier studies.